Table 4. Performance of the models for no residual disease after secondary cytoreductive surgery.
| Score | Sensitivity | Specificity | PPV | NPV | Accuracy |
|---|---|---|---|---|---|
| Number of lesions PET (≤2 vs. >2) | 85.7% | 50% | 92.3% | 33.3% | 81.2% |
| AGO score (negative vs. positive) | 87.5% | 20% | 86% | 22.2% | 77.3% |
| iMODEL (low risk vs. high risk) | 92.8% | 30% | 88.1% | 42.8% | 83.3% |
| MSK criteria (no vs. offer+consider) | 96.6% | 30% | 89.1% | 60% | 87% |
| PET/CT-AGO score (negative vs. positive*) | 71.2% | 50% | 89.4% | 22.7% | 68.1% |
| PET/CT-iMODEL (negative vs. positive*) | 76.3% | 60% | 91.8% | 30% | 73.9% |
| PET/CT-MSK criteria (negative vs. positive*) | 79.7% | 60% | 92.2% | 33.3% | 76.8% |
AGO, Arbeitsgemeinschaft Gynäkologische Onkologie; MSK, Memorial Sloan Kettering; NPV, negative predictive value; PET/CT, positron emission tomography/computed tomography; PPV, positive predictive value.
*Considered positive if at least one of the two models suggested secondary cytoreductive surgery.